Circulating tumor DNA in ALK-positive anaplastic large cell lymphoma: a proof-of-concept study

Damien Vasseur; Samuel Abbou; Ludovic Lacroix; Laurence Lamant; Noémie Pata-Merci; David Sibon; Francesco Facchinetti; Marc Deloger; Floriane Braye; Véronique Minard-Colin; Laurence Brugières; Etienne Rouleau; Luc Friboulet; Charlotte Rigaud

doi:10.1038/s41698-025-00944-3

Circulating tumor DNA in ALK-positive anaplastic large cell lymphoma: a proof-of-concept study

Damien Vasseur, Samuel Abbou, Ludovic Lacroix, Laurence Lamant, Noémie Pata-Merci, David Sibon, Francesco Facchinetti, Marc Deloger, Floriane Braye, Véronique Minard-Colin, Laurence Brugières, Etienne Rouleau, Luc Friboulet, Charlotte Rigaud

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

Résumé

In this multicenter study, we were able to detect circulating tumor DNA (ctDNA) in 87.5% of patients with the rare disease ALK + ALCL. Moreover, by analyzing ctDNA from samples collected at disease progression, we were able to identify resistance mutations to ALK inhibitors. Furthermore, ctDNA proved to be a valuable and consistent tool for monitoring minimal residual disease.

langue originale	Anglais
Numéro d'article	157
journal	npj Precision Oncology
Volume	9
Numéro de publication	1
Les DOIs	https://doi.org/10.1038/s41698-025-00944-3
état	Publié - 1 déc. 2025

Accès au document

10.1038/s41698-025-00944-3

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Vasseur, D., Abbou, S., Lacroix, L., Lamant, L., Pata-Merci, N., Sibon, D., Facchinetti, F., Deloger, M., Braye, F., Minard-Colin, V., Brugières, L., Rouleau, E., Friboulet, L., & Rigaud, C. (2025). Circulating tumor DNA in ALK-positive anaplastic large cell lymphoma: a proof-of-concept study. npj Precision Oncology, 9(1), Article 157. https://doi.org/10.1038/s41698-025-00944-3

@article{3a0c5413b1574a9bb1dfc74f48965c36,

title = "Circulating tumor DNA in ALK-positive anaplastic large cell lymphoma: a proof-of-concept study",

abstract = "In this multicenter study, we were able to detect circulating tumor DNA (ctDNA) in 87.5% of patients with the rare disease ALK + ALCL. Moreover, by analyzing ctDNA from samples collected at disease progression, we were able to identify resistance mutations to ALK inhibitors. Furthermore, ctDNA proved to be a valuable and consistent tool for monitoring minimal residual disease.",

author = "Damien Vasseur and Samuel Abbou and Ludovic Lacroix and Laurence Lamant and No{\'e}mie Pata-Merci and David Sibon and Francesco Facchinetti and Marc Deloger and Floriane Braye and V{\'e}ronique Minard-Colin and Laurence Brugi{\`e}res and Etienne Rouleau and Luc Friboulet and Charlotte Rigaud",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2025.",

year = "2025",

month = dec,

day = "1",

doi = "10.1038/s41698-025-00944-3",

language = "English",

volume = "9",

journal = "npj Precision Oncology",

issn = "2397-768X",

number = "1",

}

Vasseur, D, Abbou, S, Lacroix, L, Lamant, L, Pata-Merci, N, Sibon, D, Facchinetti, F, Deloger, M, Braye, F, Minard-Colin, V, Brugières, L, Rouleau, E, Friboulet, L & Rigaud, C 2025, 'Circulating tumor DNA in ALK-positive anaplastic large cell lymphoma: a proof-of-concept study', npj Precision Oncology, VOL. 9, Numéro 1, 157. https://doi.org/10.1038/s41698-025-00944-3

TY - JOUR

T1 - Circulating tumor DNA in ALK-positive anaplastic large cell lymphoma

T2 - a proof-of-concept study

AU - Vasseur, Damien

AU - Abbou, Samuel

AU - Lacroix, Ludovic

AU - Lamant, Laurence

AU - Pata-Merci, Noémie

AU - Sibon, David

AU - Facchinetti, Francesco

AU - Deloger, Marc

AU - Braye, Floriane

AU - Minard-Colin, Véronique

AU - Brugières, Laurence

AU - Rouleau, Etienne

AU - Friboulet, Luc

AU - Rigaud, Charlotte

PY - 2025/12/1

Y1 - 2025/12/1

N2 - In this multicenter study, we were able to detect circulating tumor DNA (ctDNA) in 87.5% of patients with the rare disease ALK + ALCL. Moreover, by analyzing ctDNA from samples collected at disease progression, we were able to identify resistance mutations to ALK inhibitors. Furthermore, ctDNA proved to be a valuable and consistent tool for monitoring minimal residual disease.

AB - In this multicenter study, we were able to detect circulating tumor DNA (ctDNA) in 87.5% of patients with the rare disease ALK + ALCL. Moreover, by analyzing ctDNA from samples collected at disease progression, we were able to identify resistance mutations to ALK inhibitors. Furthermore, ctDNA proved to be a valuable and consistent tool for monitoring minimal residual disease.

UR - http://www.scopus.com/inward/record.url?scp=105006662363&partnerID=8YFLogxK

U2 - 10.1038/s41698-025-00944-3

DO - 10.1038/s41698-025-00944-3

M3 - Article

AN - SCOPUS:105006662363

SN - 2397-768X

VL - 9

JO - npj Precision Oncology

JF - npj Precision Oncology

IS - 1

M1 - 157

ER -